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To the Editor
Approximately two years ago, two of us (E.B. and V.G.) demonstrated the first experimental 
application of CRISPR-Cas9 to ‘drive’ a desired trait throughout a population of fruit flies1. 
In November 2015, this same team at the University of California, San Diego, joined with 
A.A.J. and others at the University of California, Irvine to develop a CRISPR-based gene 
drive for population modification of the malaria vector mosquito Anopheles stephensi2. A 
month later, a group in the United Kingdom applied a CRISPR-based gene drive to another 
malaria vector, Anopheles gambiae3.
Many researchers around the world, including several additional authors of this 
Correspondence, are working to apply gene editing technologies with the hope of safely and 
effectively engineering populations of insects and other pest arthropods in the wild either to 
reduce diseases, such as malaria or dengue fever, or to control agricultural pests, such as 
those that transmit the bacterium that causes citrus greening disease. Important benefits 
could be realized if these research efforts are successful, but realizing these benefits requires 
sustained, open, and inclusive attention to potential environmental and social impacts and 
regulatory and implementation challenges. Many of these challenges were outlined in the 
recent report by a committee convened by the US National Academy of Sciences, 
Engineering, and Medicine (NASEM; Washington, DC) to review the science of gene drives 
and examine considerations for their responsible use4.
In January 2016, the J. Craig Venter Institute (JCVI; La Jolla, CA) and UC San Diego 
convened a workshop to examine the governance challenges associated with the 
development and use of gene-drive modified insects. The workshop brought together leading 
gene-drive researchers with federal officials, ecologists, ethicists, environmental policy 
analysts, and others.
The meeting not only identified and discussed key challenges that scientists and decision 
makers will face as researchers develop gene-drive insects (and other pest arthropods, such 
as ticks) intended for environmental release, but also identified a series of ‘action items’ to 
help address these challenges. The resulting report5, available online, outlines specific 
suggestions for researchers and research funders, US regulators and policymakers, and 
international organizations.
Here we focus on a subset of those action items, in particular the need for ‘rules of the road’; 
that is, guidance documents about best practices to be followed at each stage of development 
of the new technology. Assembling and sharing best practices among all involved is a vital 
component for fostering responsible development, testing, and application of rapidly 
advancing technologies such as gene drives.
Gene drives are a recent advance in a long line of genetic engineering techniques, thus much 
of the task is not the production of guidance documents de novo, rather the need to update 
the guidance prepared for earlier generations of genetically engineered insects and other pest 
arthropods. Table 1 summarizes examples of important existing guidance documents, 
showing stage of product development (columns) and source of the guidance (rows). 
Underlined entries in Table 1 anticipated gene drives, although only two4,6 directly 
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addressed the latest generation of CRISPR-based gene drives. Plain text entries were 
developed for earlier generations of genetically engineered arthropods. Many of us played 
key roles in the development of the listed documents; we understand first-hand the need for 
review and updating guidance to take into consideration these very recent advances.
Governance of rapidly emerging technologies is often best achieved by a mix of self-
governance, ‘soft’ governance, and enforceable (‘hard’) governance. Guidance by 
professional societies and ad hoc groups of scientists (the top row, Table 1) provides the 
most nimble approach, therefore potentially the most responsive to a rapidly advancing 
technology, such as gene-drive modified insects4,6–11. At the other end of the spectrum are 
various forms of legal or fiduciary governance, which range from guidances (which are 
recommendations) to regulations and statutes, which have the force of law12–15. Although 
government guidances represent the best thoughts of the agencies at the time of issuance, 
these forms of governance are typically more difficult to keep current. (The table includes 
only guidance from US agencies, although many other nations have similar documents).
So-called ‘soft governance’ by regional and international organizations falls midway. These 
documents16–20 provide guidance to countries, which use them as a basis for their own 
enforceable documents, as well as directly to product developers. Because many applications 
of gene-drive modified insects are intended for use in both developed and developing 
nations, guidance from multinational organizations plays a key role.
Given the current stage of scientific development, we believe the most pressing needs with 
regard to guidance are to update and develop guidance documents that could help the 
scientific community safely move gene drive insects and other pest arthropods from the 
laboratory to field trials (Table 1, middle column), starting with best practices for field trials 
in confined cages and then developing best practices for small-scale open field tests.
Perhaps the strongest consensus to emerge during our workshop was the importance of 
incorporating community engagement prior to and during approved field testing of 
genetically engineered insects. Technical guidance is only part of the picture. There is a 
critical need for guidance on best practices for community engagement, consolidating and 
expanding lessons learned from the case studies to date9–11.
At the international level, the developers of these technologies strongly encouraged active 
engagement by the World Health Organization (WHO; Geneva, Switzerland), including an 
update to their existing guidance document for testing of genetically modified mosquitoes16. 
The phased testing pathway first developed in that report was extensively discussed both 
during our workshop and in the recent NASEM report. Although published only a few years 
ago, the WHO report does not directly address the latest generation of CRISPR-based gene 
drives. The updated framework would also be a valuable resource for international and 
regional organizations that focus on insect and other arthropod pests of agriculture.
The potential benefits are clear if these ongoing research efforts are successful; however, the 
efficacy and risks must first be carefully evaluated. To do so, we need to develop societally 
acceptable rules of the road.
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